Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 10/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14606011 | 0.88 | CCR1 (0.39) | CCR1TRPV4ATMGAACTSL | |
| SCHEMBL4132204 | 0.88 | MAPK1 (0.45) | CCR1TRPV4ATMMEN1KMT2A | |
| SCHEMBL4132203 | 0.88 | MAPK1 (0.45) | CCR1TRPV4ATMMEN1KMT2A | |
| SCHEMBL13872499 | 0.87 | AAK1 (0.46) | CCR1TRPV4ATMGAATSHR | |
| SCHEMBL14605688 | 0.85 | TRPV4 (0.41) | CCR1TRPV4GAAMEN1KMT2A | |
| SCHEMBL4768147 | 0.84 | CCR1 (0.42) | CCR1TRPV4ATMGAAFABP4 | |
| SCHEMBL14606018 | 0.84 | RAB9A (0.42) | CCR1TRPV4MEN1TSHRKMT2A | |
| SCHEMBL14605593 | 0.83 | RAB9A (0.42) | CCR1MEN1TSHRKMT2ACNR1 | |
| SCHEMBL14606012 | 0.83 | ITGAV (0.41) | CCR1TRPV4ATMGAAITGAV | |
| SCHEMBL14605858 | 0.82 | MAPT (0.39) | CCR1TRPV4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CCR1 766/4885TRPV4 1/4885ATM 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.